Saturday, 17 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

FLEXDEAL Stock Bearish By 9% So Far Today

Loading stream...

(VIANEWS) - Shares of FLEXDEAL (PSI: FLEXD.LS) dropped 9.33% to €4.76 at 11:22 EST on Monday, after five successive sessions in a row of losses. PSI is jumping 0.09% to €5,871.25, after three sequential sessions in a row of losses. This seems, up until now, a somewhat positive trend exchanging session today.

About FLEXDEAL

Flexdeal Simfe S.A. operates as a securities investment company. The company is based in Barcelos, Portugal. Flexdeal Simfe S.A. is a subsidiary of Flexdeal Participações S.A.

Earnings Per Share

As for profitability, FLEXDEAL has a trailing twelve months EPS of €0.07.

PE Ratio

FLEXDEAL has a trailing twelve months price to earnings ratio of 68. Meaning, the purchaser of the share is investing €68 for every euro of annual earnings.

Volume

Today's last reported volume for FLEXDEAL is 514 which is 2605.26% above its average volume of 19.

More news about FLEXDEAL (FLEXD.LS).

Categories

stockMarket

Tags

FLEXD.LSStock PricePrice DownMarket Session NowFLEXDEALStock Price DownStock Market NowMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com